The FDA has approved a new drug application for TNX-102 SL (Tonmya), a tablet with 2.8 mg of cyclobenzaprine HCl, after two clinical trials demonstrated the safety and effectiveness of the treatment in adults with fibromyalgia.
In comments to the CMS, the ACR advocated for telehealth flexibilities and fair reimbursement and pushed back on proposed efficiency adjustments and changes likely to increase administrative burden on practices.